Highlighting Promising TRK Inhibitors for the Treatment of Thyroid Cancer

14 May, 2019 ,
Targeted Oncology
Targeted Oncology
14 May, 2019 ,

Dr. Hong discusses potential TRK inhibitors that could be used in the treatment of patients with thyroid cancer after the approval of larotrectinib (Vitrakvi). Overall, a significant amount of patients seem to respond to larotrectinib and the responses appear very durable, Hong says. The hope with LOXO-195, another TRK inhibitor, is to see more of these significant responses and durability in these patients. Like many other small molecules, next steps include determining the mechanisms of resistance and if other drugs can be developed that are less toxic.